drugset / Trial / NCT05148767
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
NaSequentialOpen-labelTreatment
Summary
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 65 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 80 mg/m2 | — |
| Background | Capecitabine | Small molecule | 625 mg/m2 | — |
Indications
No indication recorded.